OAK trial: Checkpoint inhibitor atezolizumab > docetaxel for overall survival in patients with advanced #NSCLC http://bit.ly/2dO66PD pic.twitter.com/QuYJu6Cqz7
9:45 AM - 25 Oct 2016
0 replies
1 retweet
0 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.